Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

EMERYVILLE, Calif., Aug. 27, 2025   (Nasdaq: ), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m. ET.

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at .

About DynavaxDynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit .

For Investors/Media:Paul Cox510-665-0499

Nicole Arndt510-665-7264

SOURCE Dynavax Technologies